| Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer | 04/14/2025 | |
| Implementing Guideline-Concordant Care Into a Targeted Therapy Approach for Patients With Platinum-… | 04/15/2025 | |
| Targeted Therapy in the Treatment of Recurrent Platinum-Resistant Ovarian Cancer | 04/17/2025 | |
| First-Line Maintenance Therapy Using PARP Inhibitors for Ovarian Cancer | 04/17/2025 | |
| Implementing Guideline-Concordant Care Into the Management of Frontline Patients With Recurrent End… | 04/17/2025 | |
| Guideline Considerations for Immunotherapy in Primary Advanced or Recurrent Endometrial Cancer | 04/16/2025 | |
| Innovations in Oncology Learning Center From Guidelines to Practice: Gynecologic Cancer | | |
| Patient Case: How Do HER2-Directed Therapies Fit Into the Biliary Tract Cancer Treatment Landscape? | 04/15/2025 | |
| Patient Case: How Do HER2-Directed Therapies Fit Into the Ovarian Cancer Treatment Landscape? | 04/14/2025 | |
| Monitoring and Managing Treatment-Related Adverse Effects Associated With HER2-Directed Agents | 04/16/2025 | |
| Emerging Data Evaluating HER2-Directed Therapies in Gynecologic Cancers | 04/11/2025 | |
| Diversity in HER2 Expression Among Gynecologic Cancers | 04/13/2025 | |
| Significance of HER2 Expression in Solid Tumors | 04/16/2025 | |
| Expanding Horizons: HER2 Targeting in Metastatic Solid Tumors | | |
